Women’s healthcare firm Gynesonics has announced the full launch of Sonata 2 System, a transcervical fibroid ablation system, in the US and Europe.
It is claimed to be the first and only transcervical fibroid ablation system that brings together the intrauterine ultrasound approach with the benefits of targeted radiofrequency energy in an incision-less, uterus preserving procedure.
The Sonata 2 system comes with a next-generation intrauterine ultrasound probe with improved performance, providing higher resolution imaging, which helps to target fibroids throughout the uterus.
The system also features an improved graphic user interface to boost workflow efficiency and user experience.
Supporting the long-term efficacy of the system is a positive five-year outcomes data reported in the VITALITY study published earlier this year.
Long-term data comes following early clinical results in the SONATA pivotal trial, which had seen 95% of patients reporting a reduction in bleeding symptoms, as well as 97% of patients indicating satisfaction rate at 12 months.
Gynesonics president and CEO Christopher M Owens said: “Based on the published evidence showing durable relief of symptoms and high rates of patient satisfaction, we believe Sonata is truly a breakthrough solution for physicians and patients.
“The promising clinical results provided with the Sonata platform are rapidly gaining strong interest throughout the physician community as an innovative new treatment option for patients suffering from symptomatic uterine fibroids.”
Earlier this year, Gynesonics also announced the completion of a $75m equity financing.
Led by Bain Capital Life Sciences, the financing round included all of the company’s existing investors, including Abingworth, Endeavour Vision, HealthCrest, Advanced Technology Ventures and HBM Partners, as well as Correlation Ventures, InterWest Partners and Hercules Technology Growth Capital.